Company Information

Agenus has 22 programs in clinical development, between our own pipeline and our strategic partnerships, including three programs currently in Phase 3 clinical trials. Our goal is to build shareholder value by bringing cutting-edge immune-therapies to patients, harnessing the power of the immune system to optimize the treatment of patients with cancer and infectious diseases and to improve the prevention of disease.

Stock Chart

$ 6.11 -0.03 (-0.49%)
Volume: 876.1k
4:00 p.m. ET on August 09, 2016
Minimum 15 minute delay.